Ten percent of patients who underwent hereditary cancer MGPT between January and June 2015 at a clinical laboratory were randomly selected. TRF-reported cancer diagnoses were evaluated for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback